Just Other Articles

The January effect is predicated on the theory that investors tend to sell of their losing stocks towards the end of the year in order to write

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

the losses off on their taxes. Therefore, according to the January effect, stocks will tend to dip towards the end of the year and rebound in

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

January when tax-loss selling has ended.

The January effect is supposed to have a greater affect on small-cap stocks (as opposed to large-cap

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

s) since it is assumed that a relatively small amount of tax-loss selling will still have a significant impact on a relatively small, thinly-tr

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

aded company

Analysis of broad samples of value-weighted and equal-weighted returns of U.S. equities documents that abnormally high rates of r

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

turn on small-capitalization stocks continue to be observed during the month of January. This January effect in small-cap stock returns is rema

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

rkably consistent over time and does not appear to have been affected by passage of the Tax Reform Act of 1986. This finding brings new perspec

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

tive to the tax-loss selling hypothesis and suggests that behavioral explanations are relevant to the January effect. After a generation of int

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ensive study, the January effect continues to present a serious challenge to the efficient market hypothesis.

So there you have it Gang.... ea

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

sy huh?....Not really at all useful to those that ONLY invest in the majors....BUT ( and this is a VERY BIG BUT....no, not mine....nice try tho

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

gh )....if you are like me, and ONLY invest in small caps and/or penny stocks...THIS IS OUR TIME OF YEAR!!!!!!!

As month end is indicative of

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

back office selling ( credit departments of EVERY brokerage houses clearing off their books for adjusted loan values ), so is the end of the ye

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ar for penny stocks. I mean.... it's simple to follow....how many penny stocks that you know of this year alone, have declined in value? If you

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

're a full time VULTURE, like myself, out of every 10, and average of 6 or more will be losers....therefore, "we" sell to "book" the loss and a

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

pply it to our gains for the year ( if any..)....are you following me?.....so....if you've done your own DD on a few "juicy" penny plays and ar

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

finding yourself at a loss.... you may not be a loser after all.......if your stock is thinly traded....but trades regularly ( VERY IMPORTANT-

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

---PLEASE PAY CLOSE ATTENTION TO THAT )....SELL your position ON Dec.31 before noon.

Get a VERY comfortable blanket and some coffee and be pre

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

pared to sleep next to your computer ( or have your finger on speed dial to your Broker )....on Jan. 2 ( Not 1st as we're closed ) at 6:30am...

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

.BUY back in....more than likely, you'll be buying back at levels slightly lower than where you sold the day earlier...TADA!....you're already

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ahead for 2007!

Pretty elaborate spam on that one, we don't suggest anyone buy anything here, sorry, Thanks for the rest of your report though

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.justotherarticles.org.ua/article/89679/justotherarticles-The-January-Effect-and-how-it-relates-to-Small-Caps-or-Penny-Stocks.html">The January Effect and how it relates to Small Caps, or Penny Stocks</a>

BB link (for phorums):
[url=http://www.justotherarticles.org.ua/article/89679/justotherarticles-The-January-Effect-and-how-it-relates-to-Small-Caps-or-Penny-Stocks.html]The January Effect and how it relates to Small Caps, or Penny Stocks[/url]

How would you like to increase your adsense profits, almost triple fold, in just 7days or less? Well it is possible if you are willing to work at it.

There is a thin hairline difference between the terms web site submission and search engine submission. Search engine submission of a web site is specific for only search engines and may not include useful directories and other classification web sites. When we use the first term it is generalizing the process of making our presence known on Internet. ...

The web as they call it is a mesh of links. The wired world is now being counted for what it is. A Network. The more your pages are wired or integrated into the overall web linking architecture, the better it is from search engine ranking point of view.

Tags

Links

Just Other Articles - The January Effect and how it relates to Small Caps, or Penny Stocks

Related Articles: